Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Richard Sam, Emory Ryan, Emily Daykin & Ellen Sidransky. (2021) Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opinion on Pharmacotherapy 22:11, pages 1489-1503.
Read now
Read now
Ramon Cacabelos. (2020) Pharmacogenomics of drugs used to treat brain disorders. Expert Review of Precision Medicine and Drug Development 5:3, pages 181-234.
Read now
Read now
Qiong Wang, Haiyun Wang, Youyan Zhong & Qiang Zhang. (2019) Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats. Drug Design, Development and Therapy 13, pages 4207-4213.
Read now
Read now
Olive Jung, Samarjit Patnaik, Juan Marugan, Ellen Sidransky & Wendy Westbroek. (2016) Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Review of Proteomics 13:5, pages 471-479.
Read now
Read now
Articles from other publishers (26)
Vaibhav Jain, Sandra L. Harper, Amanda M. Versace, Dylan Fingerman, Gregory Schuyler Brown, Monika Bhardwaj, Mary Ann S. Crissey, Aaron R. Goldman, Gordon Ruthel, Qin Liu, Aleksandra Zivkovic, Holgar Stark, Meenhard Herlyn, Phyllis A. Gimotty, David W. Speicher & Ravi K. Amaravadi. (2023) Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. Cancer Discovery 13:2, pages 454-473.
Crossref
Crossref
Casey L. Mahoney-Crane, Megha Viswanathan, Dreson Russell, Rachel A.C. Curtiss, Jennifer Freire, Sai Sumedha Bobba, Sean D. Coyle, Monika Kandebo, Lihang Yao, Bang-Lin Wan, Nathan G. Hatcher, Sean M. Smith, Jacob N. Marcus & Laura A. Volpicelli-Daley. (2023) Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions. The Journal of Neuroscience 43:3, pages 501-521.
Crossref
Crossref
James A. Shayman, Vania Hinkovska-Galcheva & Liming Shu. 2023. Glycolipids. Glycolipids
271
288
.
M.Á. Torralba-Cabeza, M. Morado-Arias, A. Pijierro-Amador, M.C. Fernández-Canal & J. Villarrubia-Espinosa. (2022) Recommendations for oral treatment for adult patients with type 1 Gaucher disease. Revista Clínica Española (English Edition) 222:9, pages 529-542.
Crossref
Crossref
M.Á. Torralba-Cabeza, M. Morado-Arias, A. Pijierro-Amador, M.C. Fernández-Canal & J. Villarrubia-Espinosa. (2022) Recomendaciones para el tratamiento oral de pacientes adultos con enfermedad de Gaucher tipo 1. Revista Clínica Española 222:9, pages 529-542.
Crossref
Crossref
Younggyu Kong, Pulla Reddy Boggu, Gi Min Park, Yeon Su Kim, Seong Hwan An, In Su Kim & Young Hoon Jung. (2022) Total Synthesis of Eliglustat via Diastereoselective Amination of Chiral para-Methoxycinnamyl Benzyl Ether. Molecules 27:8, pages 2603.
Crossref
Crossref
Wouter J. C. Feitz, Romy Bouwmeester, Thea J. A. M. van der Velden, Susan Goorden, Christoph Licht, Lambert P. J. W. van den Heuvel & Nicole C. A. J. van de Kar. (2021) The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS. Microorganisms 9:10, pages 2157.
Crossref
Crossref
Qing‐Chun Zhang, Zuo‐Lin Lu, Chen Hu, Kejie Zhu, Meifen Jiang, Zedu Huang & Fener Chen. (2021)
Enantio‐ and Diastereoselective Synthesis of Chiral
Syn
‐Aryl β‐Hydroxy α‐Amino Esters via Biocatalytic Dynamic Reductive Kinetic Resolution
. Asian Journal of Organic Chemistry 10:7, pages 1700-1703.
Crossref
Crossref
Ana Camila Vásquez-Salazar & Alfredo Uribe-Ardila. (2021) Análisis de beta-glucosidasa en sangre seca recolectada en papel filtro (DBS), reporte de un nuevo método aplicado a población control y pacientes con sospecha de enfermedad de Gaucher. Revista Med 28:2, pages 35-48.
Crossref
Crossref
Young Bae Sohn, Yewon Kim & Ji Eun Moon. (2020) One-year experience of oral substrate reduction therapy in three patients with Gaucher disease type I. Journal of Genetic Medicine 17:2, pages 62-67.
Crossref
Crossref
Mahmudul Hasan, Kazi Faizul Azim, Md. Abdus Shukur Imran, Ishtiak Malique Chowdhury, Shah Rucksana Akhter Urme, Md. Sorwer Alam Parvez, Md. Bashir Uddin & Syed Sayeem Uddin Ahmed. (2020) Comprehensive genome based analysis of Vibrio parahaemolyticus for identifying novel drug and vaccine molecules: Subtractive proteomics and vaccinomics approach. PLOS ONE 15:8, pages e0237181.
Crossref
Crossref
Tae-Un Han, Richard Sam & Ellen Sidransky. (2020) Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Ellen Sidransky, David Arkadir, Peter Bauer, Tama Dinur, Grisel Lopez, Arndt Rolfs & Ari Zimran. (2019)
Substrate Reduction Therapy for
GBA1
‐Associated Parkinsonism: Are We Betting on the Wrong Mouse?
. Movement Disorders 35:2, pages 228-230.
Crossref
Crossref
Anna Kovilakath & L. Ashley Cowart. (2020) Sphingolipid Mediators of Myocardial Pathology. Journal of Lipid and Atherosclerosis 9:1, pages 23.
Crossref
Crossref
Yanyan Peng, Benjamin Liou, Venette Inskeep, Rachel Blackwood, Christopher N Mayhew, Gregory A Grabowski & Ying Sun. (2019) Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease. Human Molecular Genetics 28:20, pages 3406-3421.
Crossref
Crossref
Venkata Krishna Reddy, Narayana Swamy, Rajeswari Rathod & Pinaki Sengupta. (2019) A Bioanalytical Method for Eliglustat Quantification in Rat Plasma. Journal of Chromatographic Science 57:7, pages 600-605.
Crossref
Crossref
Guodong Sun, Weilin Jian, Zhonghua Luo, Tengfei Sun, Chao Li, Jiancun Zhang & Zhongqing Wang. (2019) Development of an Efficient and Scalable Asymmetric Synthesis of Eliglustat via Ruthenium(II)-Catalyzed Asymmetric Transfer Hydrogenation. Organic Process Research & Development 23:6, pages 1204-1212.
Crossref
Crossref
Kunal C. Potnis, Lauren B. Flueckinger, Christine I. Ha, Jariya Upadia, Donald P. Frush & Priya S. Kishnani. (2019) Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy. Molecular Genetics and Metabolism 126:2, pages 157-161.
Crossref
Crossref
Luba NalysnykRebecca SugarmanClifford CeleJennifer UyeiAlexandra Ward. (2018) Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States. Journal of Managed Care & Specialty Pharmacy 24:10, pages 1002-1008.
Crossref
Crossref
Mirjam Langeveld, Deborah Elstein, Jeff Szer, Carla E.M. Hollak & Ari Zimran. (2018) Classifying the additional morbidities of Gaucher disease. Blood Cells, Molecules, and Diseases 68, pages 209-210.
Crossref
Crossref
Marina Cadena Matta, Filippo Vairo, Leuridan Cavalcante Torres & Ida Schwartz. (2018) Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1?. Blood Cells, Molecules, and Diseases 68, pages 200-202.
Crossref
Crossref
Joanna Kenny, Elizabeth Forsythe, Philip Beales & Chiara Bacchelli. (2017) Toward personalized medicine in Bardet–Biedl syndrome. Personalized Medicine 14:5, pages 447-456.
Crossref
Crossref
Peter J. Meikle & Scott A. Summers. (2016) Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nature Reviews Endocrinology 13:2, pages 79-91.
Crossref
Crossref
Scott A. Sands & Steven M. LeVine. (2016) Substrate reduction therapy for Krabbe's disease. Journal of Neuroscience Research 94:11, pages 1261-1272.
Crossref
Crossref
Ilona Tkachyova, Xiaolian Fan, Anne-Marie LamHonWah, Bohdana Fedyshyn, Ingrid Tein, Don J. Mahuran & Andreas Schulze. (2016) NDST1 Preferred Promoter Confirmation and Identification of Corresponding Transcriptional Inhibitors as Substrate Reduction Agents for Multiple Mucopolysaccharidosis Disorders. PLOS ONE 11:9, pages e0162145.
Crossref
Crossref
Clyde F. Phelix, Allen K. Bourdon, Greg Villareal & Richard G. LeBaron. (2016) Modeling non-clinical and clinical drug tests in Gaucher disease. Modeling non-clinical and clinical drug tests in Gaucher disease.